14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
UK vs AAPG: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
UK Wins Head-to-Head Institutional Verdict (2–2 across 6 Pillars · 5–5 Matrix Metrics)
UK Overall Winner
6-Pillar Tally: UK 2 – 2 AAPG (2 Tie)
Matrix Metrics: UK 5 – 5 AAPG
As of Nov 20, 2026, Ucommune International Ltd (UK) is the stronger overall head-to-head candidate over Ascentage Pharma Group International American Depository Shares (AAPG) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow). UK carries a Unified Composite Score of 41.3/100 (SELL) at $1.10 (N/M Forward P/E, -146.0% operating margin), whereas AAPG carries 37.1/100 (SELL) at $11.97 (8.4x Forward P/E, -219.5% operating margin).
Growth vs. Quality Trade-Off: UK earns the overall head-to-head edge with a stronger Unified Composite Score (41.3/100 SELL vs. AAPG 37.1/100 SELL) and 7.12β · 83% Vol risk profile, whereas AAPG leads top-line expansion (+29.3% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates.
Defensive Composite Rating Caution: Although UK compares more favorably head-to-head, both UK (41.3/100 SELL) and AAPG (37.1/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
Technical & Structure Timing Caution: UK is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 22.9); meanwhile AAPG is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on UK vs AAPG. Trailing 12-month operating profitability (UK -146.0% vs AAPG -219.5%) and valuation multiples (UK N/M vs AAPG 8.4x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $1.2B market capitalization and -219.5% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ UK vs AAPG Key Questions & Quantitative Answers
As of Nov 20, 2026, Ucommune International Ltd (UK) is the stronger overall head-to-head candidate over Ascentage Pharma Group International American Depository Shares (AAPG) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow). UK carries a Unified Composite Score of 41.3/100 (SELL) at $1.10 (N/M Forward P/E, -146.0% operating margin), whereas AAPG carries 37.1/100 (SELL) at $11.97 (8.4x Forward P/E, -219.5% operating margin). Growth vs. Quality Trade-Off: UK earns the overall head-to-head edge with a stronger Unified Composite Score (41.3/100 SELL vs. AAPG 37.1/100 SELL) and 7.12β · 83% Vol risk profile, whereas AAPG leads top-line expansion (+29.3% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates. Defensive Composite Rating Caution: Although UK compares more favorably head-to-head, both UK (41.3/100 SELL) and AAPG (37.1/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model. Technical & Structure Timing Caution: UK is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 22.9); meanwhile AAPG is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
AAPG leads the Growth & Scale pillar: UK posts -45.4% YoY revenue growth and +0.0% YoY earnings growth on $26M TTM revenue (-2.9% gross margin, -146.0% operating margin), compared with AAPG at +29.3% YoY revenue growth and +0.0% YoY earnings growth on $643M TTM revenue (93.9% gross margin, -219.5% operating margin). On trailing 12-month operating scale, UK generates $26M in USD-normalized revenue versus $643M for AAPG. In operating R&D and SG&A reinvestment, UK deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for AAPG.
AAPG screens cheaper on headline valuation multiples. UK trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (-133.6% EBITDA margin), whereas AAPG trades at 8.4x Forward P/E, 8.4x Trailing P/E, N/M PEG, and 1.8x EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against UK (-26.1% ROE) versus AAPG (-236.6% ROE) capital efficiency.
In options market volatility and institutional positioning, UK carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (7.12β · 83% Vol realized risk). By comparison, AAPG carries N/A implied volatility (N/A, Unclassified), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.36β · 64% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.